A $1B Acquisition Gives Novartis a Way to Stand Out in Crowded Area of Cancer
Frank Vinluan / medcitynews - Myricx Bio brings to Novartis antibody drug conjugates with a novel cancer-killing payload called an NMT inhibitor. Novartis says Myricx’s drugs could have advantages over currently available ADCs as well as those still in clinical development. The post A…
AI Summary: Novartis has struck a roughly $1 billion deal to acquire Myricx Bio, a preclinical bet aimed at securing a novel antibody‑drug conjugate payload. The move is a clear attempt to stand out in a crowded oncology market by buying potential innovation rather than inventing it in‑house — or, as finance folks call it, buying optionality.
Founder of telehealth startup Done sentenced to six years in prison for Adderall fraud scheme
fiercehealthcare - Ruthia He, the founder and former chief executive officer of telehealth startup Done Global, was sentenced to six years in prison on Tuesday and fined $1 million in connection with an Adderall fraud scheme.
AI Summary: A federal judge sentenced the founder of a telehealth startup to six years in prison following conviction in an Adderall‑prescribing fraud scheme. Regulators and prosecutors say the case exposes how virtual care can be gamed to fuel illegal controlled‑substance distribution, and the verdict signals tougher enforcement is coming for bad actors hiding behind telemedicine’s convenience.
Gene clues reveal why some rare leukemia patients resist tagraxofusp therapy
medicalxpress - Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia, called blastic plasmacytoid dendritic cell neoplasm (BPDCN), eventually develop resistance to tagraxofusp, the first Food and …
AI Summary: Researchers have identified decreased TXNRD1 and related molecular changes that appear linked to resistance against tagraxofusp in BPDCN patients. This insight exposes a plausible resistance mechanism and opens opportunities to test predictive biomarkers or combination strategies to overcome failure, which is welcome news for clinicians facing a stubborn, high‑risk disease.
First-in-human immunotherapy more than doubles progression-free survival in glioblastoma patients
medicalxpress - Glioblastoma, the most aggressive malignant brain tumor in adults, remains one of the most challenging cancers to treat because of limited treatment options and a poor prognosis. Patient outcomes have remained largely unchanged in the past two decades, un…
AI Summary: A first‑in‑human immunotherapy study in recurrent glioblastoma reported a more than twofold improvement in progression‑free survival, drawing attention to anti‑LAG‑3 strategies with or without anti‑PD‑1. While early and limited, the results provide a rare hint of efficacy in a notoriously treatment‑resistant cancer and warrant expedited follow‑up.
Tampa General sues Eli Lilly over pulled 340B discounts
Ella Jeffries / beckershospitalreview - Tampa General (Fla.) Hospital has sued Eli Lilly and Lilly USA, alleging the drugmaker’s decision to cut off the hospital’s 340B pricing access violates Florida’s Deceptive and Unfair Trade Practices Act. According to the July 2 complaint, filed in the U.…
AI Summary: Tampa General Hospital has filed suit against Eli Lilly after the company suspended discounts tied to the 340B drug-pricing program, alleging the move harmed hospitals that rely on those savings to fund patient care. The litigation highlights ongoing tensions over manufacturer discount policies and financial pressures on safety-net providers.
Thousands of Medicare Beneficiaries Thought Their Drug Plan Was Free. Then They Lost It.
Susan Jaffe / kffhealthnews - Thousands of people who had a Medicare drug plan with zero-dollar premiums last year got small premium increases this year — and didn’t know it. They were dropped from their coverage for failing to pay amounts as little as $8, and most can’t get it again …
AI Summary: Investigations reveal that many Medicare beneficiaries who believed their drug coverage was free later discovered they had lost benefits, often because of plan changes or confusing enrollment processes. The situation exposed gaps in consumer communication and program oversight, prompting calls for clearer disclosures and stronger safeguards to prevent future coverage surprises.
Meningococcal B vaccine ineffective in gonorrhea prevention for men who have sex with men
medicalxpress - The meningococcal B vaccine is ineffective in gonorrhea prevention among men who have sex with men (MSM) at high risk of infection, according to findings from the world's largest randomized controlled trial (RCT) into possible efficacy published in the Ne…
AI Summary: A major study found that the meningococcal B (MenB) vaccine does not provide protection against gonorrhea in men who have sex with men, contradicting earlier hopes that cross-protection might exist. Researchers emphasize the need for dedicated gonorrhea vaccines and continued public-health measures to control rising infection rates.
For the First Time, a Cell Built From Scratch Grows and Divides
Yasemin Saplakoglu / quantamagazine - Scientists built a synthetic cell that combines more lifelike properties than ever before — proof of concept that it’s possible to bring nonliving materials to life, or something close to it, in the lab. The post For the First Time, a Cell Built From Scra…
AI Summary: Scientists have for the first time built a synthetic cell from scratch that completes a full life cycle — growing and dividing in the lab. The milestone demonstrates control over core cellular processes, opening doors for bespoke biomanufacturing and disease modelling, while reviving familiar ethical and biosafety questions. Yes, it’s breathtaking — and yes, we should probably be cautious.
Ovarian Function Suppression Plus Tamoxifen Significantly Reduces Premenopausal Breast Cancer Recurrence Over Tamoxifen and Further Reduction Is Seen When Combined with Exemestane
esmo - Findings from the SOFT and TEXT studies
AI Summary: A new analysis shows adding ovarian function suppression to tamoxifen substantially lowers recurrence in premenopausal breast cancer patients compared with tamoxifen alone, with even greater reduction when switched to exemestane. Clinicians should note the clear endocrine benefit — and patients can sigh with cautious optimism while weighing menopausal side effects.
The US is hooked on unregulated peptides. But are they effective, or even safe?
livescience - The world of peptides has exploded in wellness circles, but the benefits of injecting these gray-market molecules rest on little clinical evidence.
AI Summary: Unregulated peptide products have proliferated in the US, raising safety and efficacy concerns as federal regulators convene a contentious panel that includes proponents of these off‑label compounds. The debate highlights a market gap where hype often outpaces evidence — and where regulators must decide whether to tidy up the wild west or watch it fester.
CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis
Alexandros Rampotas, Zoë C. Wong, Isaac Gannon, Charlotte K. Brierley, Yuqi Shen, Camelia Benlabiod, / science - Science Translational Medicine, Volume 18, Issue 856, July 2026.
AI Summary: Preclinical studies show CAR‑T cells engineered to target mutant calreticulin selectively eliminate disease‑driving clones in xenografts and human organoid models of myelofibrosis. The results reveal a potentially curative approach for a previously intractable mutation‑driven disease, though safety, on‑target effects and clinical translation remain to be rigorously tested.
CheckMate 214 Updates: Nivolumab Plus Ipilimumab Versus Sunitinib in Advanced RCC
oncodaily - First-line treatment for advanced renal cell carcinoma has changed substantially with the use of immune checkpoint inhibitor-based regimens. Long-term follow-up is important to show whether these early survival and response […]
AI Summary: Long‑term CheckMate‑214 data comparing nivolumab plus ipilimumab against sunitinib in advanced renal cell carcinoma show sustained survival benefits for the immunotherapy combination at nine years. The follow‑up reinforces durable responses in a defined subgroup, helping clinicians refine long‑term treatment sequencing and expectations for metastatic RCC.
Anthropic Launches Claude Science to Court Pharma Ahead of IPO
Katie Adams / medcitynews - Anthropic unveiled Claude Science, an AI workbench designed to run — not just assist with — pharma research. The company is seeking to build out its customer base in the pharma sector as it deepens its healthcare push ahead of a widely anticipated IPO.The…
AI Summary: Anthropic has rolled out Claude Science to court pharmaceutical partners and stake a claim in drug discovery, signaling a pivot from conversational AI toward biology and chemistry workflows. The move accelerates competition in AI‑driven target ID and molecule design, promising speed and scale — and giving traditional drug hunters a new set of algorithms to either fear or befriend.
Evernorth unveils new AI-powered specialty pharmacy program, Pharmacy Forward
fiercehealthcare - Evernorth has unveiled a new specialty pharmacy program that leans on AI to support a better experience for patients with complex conditions.
AI Summary: Evernorth announced a $100 million investment to roll out an AI‑driven specialty pharmacy program designed to streamline specialty drug management, improve medication access, and optimize operations. The program blends automation and data analytics to cut friction in high‑cost therapies — promising efficiency gains if the tech behaves, which is always the question.
EMERALD-3 at ESMO GI 2026: Tremelimumab Plus Durvalumab With or Without Lenvatinib Plus TACE in Embolisation-Eligible HCC
oncodaily - In the Proffered Paper session, Joseph P. Erinjeri from New York, United States, presented updated tumour response analyses from the phase III EMERALD-3 study. The abstract, titled “Tumour response analyses […]
AI Summary: EMERALD‑3, presented at ESMO GI 2026, evaluates tremelimumab plus durvalumab with or without lenvatinib and TACE in embolisation‑eligible hepatocellular carcinoma. The trial probes whether adding systemic immunotherapy to locoregional strategies improves outcomes for patients traditionally steered toward embolisation, potentially redefining combination approaches in intermediate‑stage HCC.
Orca Bio Cell Therapy Gets Landmark FDA Nod for New Kind of Living Medicine
Frank Vinluan / medcitynews - FDA approval of Orca Bio’s Tregzi makes it the first cell therapy based on regulatory T cells, or Tregs. Clinical trial results showed reduced risk of graft-versus-host disease, a common complication of the allogeneic stem cell transplants that are a stan…
AI Summary: Orca Bio’s off‑the‑shelf allogeneic cell therapy received FDA approval, marking a milestone for engineered living medicines. Regulators cleared the product after pivotal efficacy and manufacturing data, offering broader access to cellular therapy but spotlighting cost, supply logistics and the need for robust post‑market safety surveillance.
'Polypill' for heart failure cuts hospitalizations and ER visits by 60% in trial
medicalxpress - A "polypill" combining three medications recommended to treat heart failure into a single daily dose proved far more effective for patients than taking the drugs separately, a randomized clinical trial led by UT Southwestern Medical Center researchers sho…
AI Summary: The POLY‑HF randomized trial found that a fixed‑dose 'polypill' for heart failure with reduced ejection fraction cut hospitalizations and emergency visits by roughly 60%, improving adherence and standardizing therapy. Results suggest a pragmatic, low‑complexity intervention could deliver substantial health‑system benefits if adopted broadly and monitored for implementation challenges.
Bacteria-killing viruses redirect vaccine immunity to destroy cancer
newscientist - Phages, viruses that infect bacteria, could be genetically manipulated to destroy cancerous cells using the immunity we have acquired from vaccines
AI Summary: Researchers show bacteriophages can redirect existing vaccine‑induced immunity to attack cancer cells, effectively hijacking antiviral immune memory to target tumours. This clever preclinical strategy repurposes phages as delivery vehicles and immunomodulators, opening a potential new class of off‑the‑shelf immunotherapies that could complement or bypass current T‑cell approaches — if it survives the usual valley of translation.
Cancer drug shortage renews calls for federal action
medicalxpress - Cancer doctors across the United States are running short of essential generic chemotherapy drugs, and some fear the squeeze could force widespread rationing, The New York Times reported.
AI Summary: Hospitals and oncology clinics are facing critical shortages of key chemotherapy agents, forcing clinicians to consider rationing or alternative regimens. The supply squeeze has reignited demands for federal intervention, supply‑chain fixes, and clearer contingency plans to protect patients who can’t exactly wait for bureaucratic miracles.
A Bridge to Nowhere? Medicare’s GLP-1 Coverage Expansion Requires A More Holistic Approach To Weight Management
Sandeep Palakodeti / medcitynews - For seniors, the change in policy will dramatically expand access to a revolutionary medication. But there are also significant risks.The post A Bridge to Nowhere? Medicare’s GLP-1 Coverage Expansion Requires A More Holistic Approach To Weight Management …
AI Summary: Medicare’s planned GLP‑1 coverage “bridge” has kicked off a scramble: policy analysts warn a narrow drug‑centric approach won’t fix weight management, while major retailers are rolling out programs and partnerships to plug access gaps. Expect patchwork solutions, eager pharmacies, and a chorus asking for a more holistic long‑term plan.
- Clinical risks and long-term effectiveness debate (5)
- Medicare Bridge rollout, eligibility and cost questions (5)
- Online prescribing, oversight and soaring GLP‑1 use (4)
- Retailers, pharmacies and manufacturers rush to plug access gaps (4)
- All Other Stories